The 2022 ACC Heart Failure Guidelines: What Do They Mean for Your Practice?
Published: 27 June 2022
-
Views:
7148
-
Likes:
7
-
Views:
7148
-
Likes:
7
-
6m 39s
-
28m 52sPart 1 The ACC Heart Failure Guidelines 2022: What Did We Learn? Biykem Bozkurt, Andrew JS Coats, Mikhail Kosiborod
Overview
Taking the recent ACC heart failure guideline updates as its core theme, this symposium, part of Heart Failure Online 2022, provides a succinct overview of the changes with one of the guideline’s primary authors.
The faculty then consider how guidelines have evolved to accommodate the growing number of foundational treatments for heart failure and how we are moving towards personalised care. We also take a look at HFpEF, and assess how our treatment options have changed and what else can be expected for this population.
Key Learning Objectives
Upon participation in this programme physicians should be able to:
- Summarise the main updates to the 2022 ACC heart failure (HF) guidelines
- Compare updates from the ACC with the 2021 ESC HF guidelines
- Recall guideline recommendations for the initiation of foundational therapy for heart failure
- Adopt foundational GMDT early in the disease course
- Postulate how ejection fraction will be used in future trials and in future guidelines
- Review existing and forthcoming trial evidence on SGLT-2 inhibitors in HFpEF
Target Audience
- Heart Failure Specialists
- General Cardiologists
- General Practitioners (GPs)
- Nurses, Pharmacists, and other Allied Healthcare Professionals
More from this programme
Part 1
The ACC Heart Failure Guidelines 2022: What Did We Learn?
Part 2
The Future of Guidelines: Towards Personalised Care?
Part 3
HFpEF: The Final Chapter in the Heart Failure Story?
Faculty Biographies
Mikhail Kosiborod
Cardiologist
Dr Mikhail Kosiborod is a cardiologist, the Vice President of Research at Saint Luke's Health System, and Professor of Medicine at the University of Missouri-Kansas City, US.
He is also Director of Cardiometabolic Research and Co-Director of the Saint Luke’s Michael & Marlys Haverty Cardiometabolic Center of Excellence at Saint Luke's Mid America Heart Institute. Dr Kosiborod is an internationally-recognised expert in the fields of diabetes and cardiovascular disease, cardiometabolic and cardiorenal syndromes.
Dr Kosiborod is involved in the leadership of numerous clinical trials and multi-center registries, and is currently the principal investigator of several investigator-initiated, multi-center trials in diabetes and cardiovascular disease.